MyAmyloidosisTeam

Here's a look at median survival rates for cardiac ATTR amyloidosis, broken down by stage. Staging is based on two key biomarkers: NT-proBNP (a heart stress marker) and eGFR (a kidney function marker).

Cardiac ATTR Amyloidosis Staging:

- Stage 1 – Both biomarkers are in the normal range → median survival of 5.8 years
- Show Full Answer

Here's a look at median survival rates for cardiac ATTR amyloidosis, broken down by stage. Staging is based on two key biomarkers: NT-proBNP (a heart stress marker) and eGFR (a kidney function marker).

Cardiac ATTR Amyloidosis Staging:

- Stage 1 – Both biomarkers are in the normal range → median survival of 5.8 years
- Stage 2 – One biomarker is outside the normal range → median survival of 3.9 years
- Stage 3 – Both biomarkers are outside the normal range → median survival of ~2 years It's worth noting that these figures reflect outcomes without treatment. Today's therapies are making a real difference — some people are now living over a decade after diagnosis.

Early diagnosis and starting treatment promptly are among the most important factors in improving outcomes. Talking with your care team about where you fall in this staging system can help guide the best treatment path forward.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Stages of Amyloidosis: Breakdown by Type and More

What Is hATTR Amyloidosis? 6 Key Facts To Know